Integra LifeSciences Organizes Hands-on Wound Workshop on Best Practices for Omnigraft® Dermal Regeneration Matrix and PriMa...
October 17 2016 - 8:30AM
Integra LifeSciences Holdings Corporation (Nasdaq:IART) recently
organized a hands-on regenerative wound management workshop at the
Symposium on Advanced Wound Care (SAWC) Fall meeting in Las Vegas,
Nevada. The workshop, led by renowned wound care experts John
Lantis, MD, and Paul Kim, DPM, focused on best practices for
outpatient chronic wound management, including the use of Integra®
dermal regenerative technologies in the chronic wound environment.
A unique combination of a hands-on skills lab and lecture attracted
surgeons, physicians, and mid-level healthcare providers.
“Many chronic wounds need more than just re-epithelialization
strategies,” said Dr. Kim, a leading foot and ankle surgeon at
Georgetown University Hospital. “This workshop highlighted the
importance of good wound care practices, such as good wound bed
preparation, to maximize the benefits of dermal regeneration
technologies.”
Additionally, nine posters were presented by surgeons and wound
care specialists on their latest clinical experiences, using
Integra products for wound management. These posters featured the
use of PriMatrix for the management of full-thickness chronic
wounds and complex pressure ulcer reconstructions as well as a
sub-analysis of the Omnigraft® FOot Ulcer New DErmal Replacement
(FOUNDER) study.
John Lantis, MD, a leading vascular surgeon at Mount Sinai St
Luke's and Mount Sinai West Hospitals, independently presented his
work on using PriMatrix for the management of complex wounds with
exposed subcutaneous structures.
“Providing optimal wound care is essential in helping our
patients enhance their quality of life,” said Dr. Lantis.
“PriMatrix has become an important part of my limb preservation
practice and helps me treat patients with very challenging
wounds.”
The SAWC serves as a forum to connect physicians, nurses,
clinical researchers and scientists with leading experts in wound
care, improving patient outcomes through collaboration and
education. More than 1,300 healthcare professionals attended the
Fall meeting.
About the FOUNDER Study The FOot Ulcer New
DErmal Replacement (FOUNDER) study was a multi-center, randomized,
controlled, parallel group clinical trial conducted under an
Investigational Device Exemption (IDE). The pivotal clinical trial
enrolled 307 patients at 32 sites, and patients were followed for
up to 29 weeks. The primary endpoint of the study was the incidence
of complete wound closure at 16 weeks. The secondary outcome
measures included time to complete wound closure, incidence of
recurrence, and quality of life. The median number of applications
per patient, including the initial application, for the IDRT group
was one. The results from the FOUNDER study were printed in the
November/December issue of Wound Repair and Regeneration in the
publication, "A Clinical Trial of Integra® Template for Diabetic
Foot Ulcer Treatment."
About Omnigraft® Dermal Regeneration
MatrixOmnigraft® Dermal Regeneration Matrix is the only
FDA approved product that regenerates dermal tissue. It is an
advanced bi-layer dermal regeneration matrix indicated for use in
the treatment of partial and full-thickness neuropathic diabetic
foot ulcers (DFUs) that are greater than six weeks in duration,
with no capsule, tendon or bone exposed, when used in conjunction
with standard diabetic ulcer care. Based on the FOUNDER study,
Omnigraft increases the incidence of wound closure by 59%,
increases the average rate of wound size closure by 50%, and
reduces the median time to wound closure by five weeks, compared to
conventional therapy. Additionally, Omnigraft healed patients with
fewer applications, with 92% of those who healed requiring two
applications or fewer.
About PriMatrix® Dermal Repair
ScaffoldPriMatrix® Dermal Repair Scaffold is a unique
dermal repair scaffold made with proprietary processing technology
that purifies fetal bovine dermis and preserves the beneficial
properties of the natural fetal dermal collagen fibers. PriMatrix
is indicated for the management of wounds that include: partial and
full thickness wounds; pressure, diabetic, and venous ulcers;
second-degree burns; surgical wounds (donor sites/grafts,
post-Moh’s surgery, post-laser surgery, podiatric, wound
dehiscence); trauma wounds (abrasions, lacerations and skin tears);
tunneled/undermined wounds; and draining wounds.
About IntegraIntegra LifeSciences Holdings
Corporation, a world leader in medical technology, is dedicated to
limiting uncertainty for clinicians, so they can concentrate on
providing the best patient care. Integra offers innovative
solutions, including leading plastic and regenerative technologies,
in specialty surgical solutions, orthopedics and tissue
technologies. For more information, please visit
www.integralife.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, but are not limited to,
statements concerning the products and services provided by
Integra. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from predicted or expected results. Among other things, the
willingness of surgical professionals to use Integra products may
affect the prospects for their use in surgical procedures. In
addition, the economic, competitive, governmental, technological
and other factors, identified under the heading "Risk Factors"
included in Item IA of Integra's Annual Report on Form 10-K for the
year ended December 31, 2015 and information contained in
subsequent filings with the Securities and Exchange Commission
could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Investors
Angela Steinway
609-936-2268
angela.steinway@integralife.com
Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com
Media
Laurene Isip
609-750-7984
laurene.isip@integralife.com
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Mar 2024 to Apr 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Apr 2023 to Apr 2024